A Phase 1 interventional study of Abemaciclib and Metformin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will look at how a single dose of abemaciclib will impact the body's ability to get rid of two other drugs, metformin and iohexol. In addition, this study will evaluate the effect of a single dose of abemaciclib on kidney function by measuring blood and urine markers. Side effects will also be documented.
Each participant will complete four study periods. During each study period, participants will stay in the clinical research unit for nine days and eight nights.
The study will last approximately 10 weeks, not including screening. Screening is required within 28 days prior to the start of the study.
This study is for research purposes only and is not intended to treat any medical condition.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
Drug: Metformin · Drug: Placebo
Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
Drug: Abemaciclib · Drug: Metformin
Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
Drug: Iohexol · Drug: Placebo
Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
Drug: Abemaciclib · Drug: Iohexol
Administered orally
Also known as: LY2835219
Administered orally
Administered intravenously (IV)
Administered orally
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of Metformin was evaluated.
Time frame: Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin was evaluated.
Time frame: Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose
Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin
Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin was evaluated.
Time frame: Pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36 hours (h) post dose
Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol
Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol was evaluated.
Time frame: Pre infusion, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6 hours post infusion
Participants were randomized to one of the four sequences and received either placebo or Abemaciclib along with Metformin or Iohexol. A washout period of at least 16 days following Abemaciclib administration \& at least 5 days following placebo administration occurred between each period.
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 11 | 11 | 9 | 9 |
| Received at least one dose of study drug | 11 | 11 | 9 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 2 | 2 | 0 | 0 |
| Withdrew: Dosing error | 2 | 2 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 7 | 9 | 8 |
| Not completed | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 9 | 7 | 9 | 8 |
| Completed | 8 | 7 | 9 | 8 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 8 | 7 | 9 | 8 |
| Completed | 8 | 7 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 8 | 7 | 9 | 8 |
| Completed | 8 | 7 | 8 | 8 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 8 | 7 | 8 | 8 |
| Completed | 8 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 8 | 7 | 7 | 7 |
| Completed | 7 | 6 | 7 | 7 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 |
| Completed | 6 | 6 | 7 | 6 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 1 |
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of Metformin was evaluated.
| Nanogram*Hour per Milliliter (ng*h/mL) | Placebo + 1000 mg Metformin | 400 mg Abemaciclib + 1000 mg Metformin |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin | 12100 ± 23 | 16800 ± 30 |
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin was evaluated.
| ng/mL | Placebo + 1000 mg Metformin | 400 mg Abemaciclib + 1000 mg Metformin |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Metformin | 1550 ± 23 | 1940 ± 31 |
Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin was evaluated.
| Liters per Hour (L/h) | Placebo + 1000 mg Metformin | 400 mg Abemaciclib + 1000 mg Metformin |
|---|---|---|
| Pharmacokinetics (PK): Renal Clearance (CLr) of Metformin | 21.5 ± 22 | 11.9 ± 35 |
Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol was evaluated.
| Milliliter per minute (mL/min) | Placebo + 5 mL Iohexol | 400 mg Abemaciclib + 5 mL Iohexol |
|---|---|---|
| Pharmacokinetics (PK): Renal Clearance (CLr) of Iohexol | 89 ± 17 | 85.6 ± 14 |
Collected over Up to 92 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + 1000 mg Metformin | — | 0/33 (0%) | 8/33 (24.2%) |
| 400 mg Abemaciclib + 1000 mg Metformin | — | 0/35 (0%) | 11/35 (31.4%) |
| Placebo + 5 mL Iohexol | — | 0/32 (0%) | 0/32 (0%) |
| 400 mg Abemaciclib + 5 mL Iohexol | — | 0/33 (0%) | 6/33 (18.2%) |
| Event | Placebo + 1000 mg Metformin | 400 mg Abemaciclib + 1000 mg Metformin | Placebo + 5 mL Iohexol | 400 mg Abemaciclib + 5 mL Iohexol |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/33 | 7/35 | 0/32 | 3/33 |
| NauseaGastrointestinal disorders | 2/33 | 4/35 | 0/32 | 4/33 |
| Abdominal PainGastrointestinal disorders | 1/33 | 4/35 | 0/32 | 0/33 |
| VomitingGastrointestinal disorders | 0/33 | 4/35 | 0/32 | 3/33 |
| FlatulenceGastrointestinal disorders | 2/33 | 1/35 | 0/32 | 0/33 |
| Age, Continuous(years) | Overall Study |
|---|---|
| Mean | 50.4 ± 10.6 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 36 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 18 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall Study |
|---|---|
| United States | 40 |
| Body Mass Index (BMI)(Kilogram per square meter (kg/m^2)) | Overall Study |
|---|---|
| Mean | 27.25 ± 3.06 |
The record gives a start of Aug 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Metformin · Iohexol